Terms: = Ovarian cancer AND CDK12, KIAA0904, CRKRS, 51755, ENSG00000167258, CRK7, CRKR, Q9NYV4 AND Treatment
12 results:
1. Dual inhibition of cdk12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
Cesari E; Ciucci A; Pieraccioli M; Caggiano C; Nero C; Bonvissuto D; Sillano F; Buttarelli M; Piermattei A; Loverro M; Camarda F; Greco V; De Bonis M; Minucci A; Gallo D; Urbani A; Vizzielli G; Scambia G; Sette C
J Exp Clin Cancer Res; 2023 May; 42(1):126. PubMed ID: 37202753
[TBL] [Abstract] [Full Text] [Related]
2. Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.
Coelho R; Tozzi A; Disler M; Lombardo F; Fedier A; López MN; Freuler F; Jacob F; Heinzelmann-Schwarz V
Cell Death Dis; 2022 Oct; 13(10):909. PubMed ID: 36307400
[TBL] [Abstract] [Full Text] [Related]
3. Dual Inhibition of cdk12/CDK13 Targets Both Tumor and Immune Cells in ovarian cancer.
Cheng L; Zhou S; Zhou S; Shi K; Cheng Y; Cai MC; Ye K; Lin L; Zhang Z; Jia C; Xiang H; Zang J; Zhang M; Yin X; Li Y; Di W; Zhuang G; Tan L
Cancer Res; 2022 Oct; 82(19):3588-3602. PubMed ID: 35857807
[TBL] [Abstract] [Full Text] [Related]
4. A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent ovarian cancer (KGOG 3044/EBLIN).
Lee YJ; Seol A; Lee M; Kim JW; Kim HS; Kim K; Suh DH; Kim S; Kim SW; Lee JY
In Vivo; 2022; 36(4):1949-1958. PubMed ID: 35738633
[TBL] [Abstract] [Full Text] [Related]
5. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
[TBL] [Abstract] [Full Text] [Related]
6. SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer.
Lin L; Shi K; Zhou S; Cai MC; Zhang C; Sun Y; Zang J; Cheng L; Ye K; Ma P; Shen P; Zhang M; Cheng Y; Qi C; Li Y; Yin X; Zheng Y; Tan L; Zhuang G; Zang R
Oncogene; 2022 Mar; 41(12):1767-1779. PubMed ID: 35124696
[TBL] [Abstract] [Full Text] [Related]
7. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Swisher EM; Kristeleit RS; Oza AM; Tinker AV; Ray-Coquard I; Oaknin A; Coleman RL; Burris HA; Aghajanian C; O'Malley DM; Leary A; Welch S; Provencher D; Shapiro GI; Chen LM; Shapira-Frommer R; Kaufmann SH; Goble S; Maloney L; Kwan T; Lin KK; McNeish IA
Gynecol Oncol; 2021 Dec; 163(3):490-497. PubMed ID: 34602290
[TBL] [Abstract] [Full Text] [Related]
8. The promise and current status of cdk12/13 inhibition for the treatment of cancer.
Tadesse S; Duckett DR; Monastyrskyi A
Future Med Chem; 2021 Jan; 13(2):117-141. PubMed ID: 33295810
[TBL] [Abstract] [Full Text] [Related]
9. Th e role of cdk12 in tumor bio logy.
Dzimková M; Procházková J; Klát J; Kohoutek J
Klin Onkol; 2020; 33(4):260-267. PubMed ID: 32894954
[TBL] [Abstract] [Full Text] [Related]
10. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
[TBL] [Abstract] [Full Text] [Related]
11. cdk12: an emerging therapeutic target for cancer.
Lui GYL; Grandori C; Kemp CJ
J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
[TBL] [Abstract] [Full Text] [Related]
12. Lentivirus-mediated RNA Interference Targeting LAPTM4B Inhibits Human ovarian cancer Cell Invasion In Vitro.
Meng F; Chen X; Song H; Lou G; Fu S
Chem Biol Drug Des; 2016 Jan; 87(1):121-30. PubMed ID: 26247403
[TBL] [Abstract] [Full Text] [Related]
